GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch.
|Articles|September 22, 2015
- Pharmaceutical Commerce - September/October 2015
Cold Chain 2015 Directory
Advertisement
Articles in this issue
about 11 years ago
Maintaining your digital marketing assetsabout 11 years ago
Cold Chain Global Forum takes shapeabout 11 years ago
Driving Traceability Requirements to True Business Valueabout 11 years ago
Next-Generation Serializationabout 11 years ago
A Conversation with Steve Collis, AmerisourceBergenabout 11 years ago
The quality drive at contract manufacturersabout 11 years ago
The 2015 Biopharma Cold Chain Landscapeabout 11 years ago
Pharma is under-managing its multi-channel marketing effortsabout 11 years ago
Predicting pharma's data-driven futureAdvertisement
Related to this article
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal discusses reusable shippers, PCM innovation and AI's role in cold chain risk.
CSafe's Aaron Mantia explains how lane, temperature range, duration and product cost shape thermal protection choices for bulk air cargo.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and consolidates cold storage.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
At LogiPharma USA 2026, Cold Chain Technologies' Anthony "TJ" Rizzo discusses cold chain expertise gaps and how data tools are reshaping the profession.
Zoomlogi's Henry Ames explains how AI agents and digitized SOPs help quality managers decide on quarantine or release after a cold chain excursion.
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal explains how predictive monitoring and right-sized packaging cut excursion risk and waste.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Walgreens Expands GLP-1 Access With Prior Authorization, Pharmacist Support
2
Large Pharma vs. Emerging Biotech: Two Launch Playbooks
3
What DOL’s Final PBM Rule Means for Rebates and Formularies
4
Pharma Pulse: GoodRx Opens Employer GLP-1 Channel, Lilly Fends Off Novo Ad Challenge, PCMA Takes Aim at Wholesalers
5